A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
Clinical trial NCT04123886 · COMPLETED
Trial details
- NCT number
- NCT04123886
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-08
- Primary completion
- 2021-09-30
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.